Product Description
Mechanisms of Action: NMDA Antagonist,Excitatory Amino Acid Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Global Coalition for Adaptive Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Depressive Disorder, Major|Stress Disorders, Post-Traumatic|Suicidality
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| S-21-02 / IND 157676 | P2 |
Recruiting |
Stress Disorders, Post-Traumatic |
2026-03-01 |
|
| S-21-02 (SLS-002) | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2026-03-01 |
|
| SLS-002-201 | P2 |
Completed |
Depressive Disorder, Major|Suicidality |
2023-06-17 |
32% |
| IRB00331675 | P2 |
Not yet recruiting |
Depressive Disorder, Major|Suicidality |
2023-03-15 |